hi everyone i have asked this before but didnt get any answers does anyone take FAMPYRA

[mollymoomoo]

i want to know whats it been tested on ie animals also wot side effects it has can anyone help

[foreversummer]

I'm sorry I don't know what it is. Can you give us a little more info and perhaps some links.

Foreversummer

[Hidden]

I understand it is used for help with walking problems as part of MS. There seems to be quite a lot of information about it on the web, especially from the MS society I think.

Have you contacted the makers for info about its development, testing methods etc?

[Hidden in reply to Hidden]

It is known also as fampyridine:

4.3 Contraindications

Hypersensitivity to fampridine or to any of the excipients listed in section 6.1.

Concurrent treatment with other medicinal products containing fampridine (4-aminopyridine).

Patients with prior history or current presentation of seizure.

Patients with mild, moderate or severe renal impairment (creatinine clearances <80 ml/min).

Concomitant use of Fampyra with medicinal products that are inhibitors of Organic Cation Transporter 2 (OCT2) for example, cimetidine.

4.4 Special warnings and precautions for use

Seizure risk

Treatment with fampridine increases seizure risk (see section 4.8).

Fampyra should be administered with caution in the presence of any factors which may lower seizure threshold.

Fampyra should be discontinued in patients who experience a seizure while on treatment.

Renal impairment

Fampyra is primarily excreted unchanged by the kidneys. Patients with renal impairment have higher plasma concentrations which are associated with increased adverse reactions, in particular neurological effects. Determining renal function before treatment and its regular monitoring during treatment is recommended in all patients (particularly in older people in whom renal function might be reduced). Creatinine clearance can be estimated using the Cockroft-Gault formula.

Fampyra should not be administered to patients with renal impairment (creatinine clearance <80 ml/min) (see section 4.3).

Caution is required when Fampyra is prescribed concurrently with medicinal products that are substrates of OCT2 for example, carvedilol, propanolol and metformin.

Hypersensitivity Reactions

In post-marketing experience, serious hypersensitivity reactions (including anaphylactic reaction) have been reported, the majority of these cases occurred within the first week of treatment. Particular attention should be given to patients with a previous history of allergic reactions. If an anaphylactic or other serious allergic reaction occurs, Fampyra should be discontinued and not restarted.

Other warnings and precautions

Fampyra should be administered with caution to patients with cardiovascular symptoms of rhythm and sinoatrial or atrioventricular conduction cardiac disorders (these effects are seen in overdose). There is limited safety information in these patients.

The increased incidence of dizziness and balance disorder seen with Fampyra in the first 4 to 8 weeks of treatment may result in an increased risk of falls. Patients who are using walking aids should continue to use these aids as needed.

In clinical studies low white blood cell counts were seen in 2.1% of Fampyra patients versus 1.9% of patients on placebo. Infections were seen in the clinical studies as stated below. An increased infection rate and impairment of the immune response cannot be excluded.